Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2657)	6/4/2006 8:42:01 PM
From: Ian@SI	Respond to of 3044

Addition of VELCADE(R) (Bortezomib) for Injection Improved survival in Front-Line Advanced Lung Cancer -- 11-month Survival Compared to 9-Month Historic Results with a Standard of Care -- ATLANTA, June 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the final results from a Phase II study conducted by the Southwest Oncology Group (SWOG) that showed a median survival of 11 months for patients with non-small cell lung cancer (NSCLC) treated with a VELCADE based regimen. This compared favorably to the historic 9-month survival seen in past SWOG studies with a 2-drug platin-based regimen, a current standard of care, in patients with non-small cell lung cancer (NSCLC). These data were reported at the American Society of Clinical Oncology (ASCO) 42nd Annual Meeting in Atlanta, June 2-6, 2006. "These survival results are among the best our group has seen in this newly diagnosed patient population," said Angela Davies, M.D., Assistant Professor, University of California Davis Cancer Center. "Given the current lack of options for treating lung cancer, we look forward to additional studies which may support the use of bortezomib." VELCADE in Combination in Advanced NSCLC: A SWOG Phase II Trial (Abstract 7017) The Phase II single-arm, multi-institutional study led by Dr. Davies assessed the safety and efficacy of VELCADE in combination with gemcitabine (GEM) and carboplatin (CARBO) in 114 chemo-naive patients with stage IV and selected stage IIIB NSCLC. Patients received GEM 1000 mg/m2 days 1 and 8, and CARBO AUC 5 on day 1, followed one hour later by VELCADE 1.0mg/m2 days 1, 4, 8 and 11. Patients without disease progression after four cycles were able to continue with VELCADE alone. Response rate was measured using the RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. Median follow up was 13 months. Key findings include: -- Median overall survival of 11 months -- One-year survival of 47 percent with five-month progression-free survival -- Overall response rate of 20 percent; stable disease of 66 percent -- Therapy well tolerated. The most common hematological toxicities were neutropenia and thrombocytopenia and the most common non-hematological adverse events were fatigue and gastrointestinal events. NSCLC accounts for about 85 percent of all lung cancer cases(1) with an estimated prevalence of more than 170,000 new cases per year.(2) Drug choices are limited while resistance to standard treatments is common. Nearly 60 percent of those diagnosed with advanced lung cancer die within one year of diagnosis and only 15 percent of patients diagnosed with all stages of lung cancer survive after five years with the disease.(2) "This study highlights the potential survival benefit of VELCADE in solid tumors beyond hematological cancers," said Robert Tepper, M.D., President, Research & Development, Millennium. "It also aligns with our aggressive strategy to pursue the benefits of VELCADE in lung cancer." Based on these results and other positive response rates in ongoing trials, Millennium and co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) are moving forward with a clinical program to evaluate the benefits of VELCADE based regimens in treating NSCLC. The companies recently initiated two randomized Phase II studies of VELCADE, one in combination with pemetrexed and the other in combination with erlotinib, in patients with advanced or metastatic NSCLC who have failed prior chemotherapy treatment. About Non-Small Cell Lung Cancer [snip]